Evidence map›Paper›PMID 20027223›Full record

ArticlePloS one2009

A strategy for adenovirus vector targeting with a secreted single chain antibody.

Joel N Glasgow, Galina Mikheeva, Victor Krasnykh, David T Curiel

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular immunotargeting.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Joel N GlasgowDivision of Cardiovascular Disease, Departments of Medicine, Obstetrics and Gynecology, Pathology, Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama, USA. jng@uab.edu
Galina Mikheeva
Victor Krasnykh
David T Curiel
The University of Texas MD Anderson Cancer Center · USUniversity of Alabama at Birmingham · USUniversity of Alabama at Birmingham Hospital · US

Funding

Translational Applications of mda-7/IL-24 in CancerP01CA104177 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B · 2005 to 2009
$6.5M
Her2-targeted vectors for gene therapy of cancerR01CA116621 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KRASNYKH, VICTOR · 2005 to 2009
$1.6M
NCI NIH HHS 7P01 CA104177NCI NIH HHS P01 CA104177NCI NIH HHS R01 CA116621
6 · The paper itself

Abstract

backgroundSuccessful gene therapy will require targeted delivery vectors capable of self-directed localization. In this regard, the use of antibodies or single chain antibody fragments (scFv) in conjunction with adenovirus (Ad) vectors remains an attractive means to achieve cell-specific targeting. However, a longstanding barrier to the development of Ad vectors with genetically incorporated scFvs has been the biosynthetic incompatibility between Ad capsid proteins and antibody-derived species. Specifically, scFv require posttranslational modifications not available to Ad capsid proteins due to their cytoplasmic routing during protein synthesis and virion assembly. METHODOLOGY/PRINCIPAL

findingsWe have therefore sought to develop scFv-targeted Ad vectors using a secreted scFv that undergoes the requisite posttranslational modifications and is trafficked for secretion. Formation of the scFv-targeted Ad vector is achieved via highly specific association of the Ad virion and a targeting scFv employing synthetic leucine zipper-like dimerization domains (zippers) that have been optimized for structural compatibility with the Ad capsid and for association with the secreted scFv. Our results show that zipper-containing Ad fiber molecules trimerize and incorporate into mature virions and that zippers can be genetically fused to scFv without ablating target recognition. Most importantly, we show that zipper-tagged virions and scFv provide target-specific gene transfer. CONCLUSIONS/SIGNIFICANCE: This work describes a new approach to produce targeted Ad vectors using a secreted scFv molecule, thereby avoiding the problem of structural and biosynthetic incompatibility between Ad and a complex targeting ligand. This approach may facilitate Ad targeting using a wide variety of targeting ligands directed towards a variety of cellular receptors.

Indexed as

Gene Transfer TechniquesAdenoviridaeAmino Acid SequenceCapsidCell LineEpitopesGenetic VectorsHumansLeucine ZippersMolecular Sequence DataOrgan SpecificityPeptidesProtein BindingProtein MultimerizationRecombinant Fusion ProteinsSingle-Chain AntibodiesEpitopesPeptidesRecombinant Fusion ProteinsSingle-Chain Antibodies

Identifiers

PMID20027223
PMCPMC2791226
OpenAlexW2008644797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.